The facility aims to produce cell and gene therapies on a global scale, making them more accessible worldwide.
It prepares for potential commercial launches, including BlueRock Therapeutics' investigational cell therapy for Parkinson's disease, Bemdaneprocel (BRT-DA01).
The facility addresses industry-wide manufacturing capacity bottlenecks for regenerative medicines.
It's a 100,000 sq. ft. building and is Bayer's first fully electric pharmaceutical manufacturing plant, aligning with sustainability goals.
The facility offers flexible, modular space for cell culture, viral transduction, and automated filling of cell therapies.
Leverages expertise in iPSC and CAR-T characterization, process development, analytics, and clinical to commercial production.
This facility is part of Bayer's larger investments in its biologic pipeline, covering protein therapeutics, cell, and gene therapies.